|1.||Hombach, Joachim: 6 articles (12/2015 - 08/2008)|
|2.||Edelman, Robert: 4 articles (05/2013 - 03/2005)|
|3.||Roehrig, John T: 3 articles (12/2015 - 01/2005)|
|4.||Hermida, Lisset: 2 articles (07/2014 - 04/2009)|
|5.||Guillén, Gerardo: 2 articles (07/2014 - 04/2009)|
|6.||Endy, Timothy P: 2 articles (06/2014 - 09/2013)|
|7.||Halstead, Scott B: 2 articles (05/2014 - 01/2005)|
|8.||Burke, Donald S: 2 articles (09/2013 - 05/2011)|
|9.||Farrar, Jeremy: 2 articles (05/2013 - 08/2008)|
|10.||Schmitz, Julia: 2 articles (05/2013 - 09/2011)|
|1.||Dengue (Dengue Fever)
10/01/2009 - "Accurate disease surveillance and carefully monitored clinical trials will provide essential evidence concerning the efficacy of candidate dengue vaccines, which will hopefully herald a new era in dengue disease prevention."
01/01/2013 - "For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered."
10/01/2010 - "In this review, we consider the issues impacting conduct and design of dengue vaccine trials with reference to the recently published World Health Organization "Guidelines for Conduct of Clinical Trials of Dengue Vaccines in Endemic Areas." We discuss logistic, scientific and ethical challenges concerning evaluation and introduction of dengue vaccines; these range from randomized trials that establish "proof of concept" of vaccine efficacy, to post-"proof of concept" trials, particularly demonstration projects likely to be required for licensure or for the introduction of an already licensed vaccine into public use. "
02/13/2008 - "Using data gathered from a contingent valuation survey, this study estimated the willingness to pay (WTP) for a single dengue fever vaccine and the household demand function for dengue vaccines. "
12/08/2003 - "Research felt to be key to future decision-making regarding dengue vaccine introduction include: disease surveillance studies, in-country vaccine trials or pilot projects, and studies on the economic burden of dengue and the cost-effectiveness of dengue vaccines. "
11/01/2014 - "These studies provide important new information about protection from dengue virus infection that will be useful in the design and testing of new experimental dengue vaccines for humans."
05/15/2012 - "These data provide a structural basis for understanding Ab neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines."
10/01/2009 - "Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection. "
08/05/2008 - "Guidelines for the evaluation of dengue vaccines in populations exposed to natural infection. "
12/01/2000 - "These results indicate that the evaluated dengue vaccines efficiently induced humoral and cell mediated immunity comparable to natural infection with dengue virus."
07/01/2008 - "Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines."
06/19/2012 - "Currently, several kinds of dengue vaccines are in development, but only one of these candidates (a chimeric dengue-yellow fever live attenuated vaccine) has reached the stage of phase 3 clinical trials."
10/23/2008 - "In this context, Dengue 1-4 and Yellow Fever 17D-204 (YF 17D)-specific CD4 and CD8 cellular responses induced by tetravalent chimeric dengue vaccines (CYD) were analyzed in flavivirus-naive or flavivirus-immune patients. "
10/01/2011 - "Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity."
04/01/2009 - "We conclude that green monkeys develop viremia and antibody responses and therefore provide a potential model for the preclinical evaluation of novel candidates for dengue vaccines."
06/08/2009 - "Although some mice developed neurologic symptoms and/or died within 21 days of K562 injection, viremia reduction was considered to be a reliable indicator of the protective capacities of candidate dengue vaccines."
|5.||Dengue Hemorrhagic Fever
10/01/2006 - "The immune mechanisms that lead to dengue hemorrhagic fever are complex and need to be elucidated further for the development of therapeutics as well as safe and efficacious dengue vaccines."
06/19/2012 - "The latter phenomenon has been proposed to play an important role in the immunopathology of severe forms of dengue virus infections (hemorrhagic dengue fever and dengue shock syndrome) and is therefore of special relevance in the context of dengue vaccines. "
|1.||Complementary DNA (cDNA)
|2.||RNA (Ribonucleic Acid)
|5.||Antiviral Agents (Antivirals)
|7.||Proteins (Proteins, Gene)
|8.||Interferon Type I